157 related articles for article (PubMed ID: 25734397)
1. Symptoms and other factors associated with time to diagnosis and stage of lung cancer: a prospective cohort study.
Walter FM; Rubin G; Bankhead C; Morris HC; Hall N; Mills K; Dobson C; Rintoul RC; Hamilton W; Emery J
Br J Cancer; 2015 Mar; 112 Suppl 1(Suppl 1):S6-13. PubMed ID: 25734397
[TBL] [Abstract][Full Text] [Related]
2. [Clinical aspects of primary lung cancers in the cancer ward of CHUA-HUJRA Antananarivo].
Refeno V; Hasiniatsy NR; Andrianandrasana NO; Ramahandrisoa AV; Rakotonarivo JM; Maevazaka JL; Rakotovao HJ; Rafaramino F
Pan Afr Med J; 2015; 22():271. PubMed ID: 26958134
[TBL] [Abstract][Full Text] [Related]
3. Time intervals and routes to diagnosis for lung cancer in 10 jurisdictions: cross-sectional study findings from the International Cancer Benchmarking Partnership (ICBP).
Menon U; Vedsted P; Zalounina Falborg A; Jensen H; Harrison S; Reguilon I; Barisic A; Bergin RJ; Brewster DH; Butler J; Brustugun OT; Bucher O; Cairnduff V; Gavin A; Grunfeld E; Harland E; Kalsi J; Knudsen AK; Lambe M; Law RJ; Lin Y; Malmberg M; Turner D; Neal RD; White V; Weller D
BMJ Open; 2019 Nov; 9(11):e025895. PubMed ID: 31776134
[TBL] [Abstract][Full Text] [Related]
4. Guideline concordance for timely chest imaging after new presentations of dyspnoea or haemoptysis in primary care: a retrospective cohort study.
Koo MM; Mounce LTA; Rafiq M; Callister MEJ; Singh H; Abel GA; Lyratzopoulos G
Thorax; 2024 Feb; 79(3):236-244. PubMed ID: 37620048
[TBL] [Abstract][Full Text] [Related]
5. Symptoms and signs of lung cancer prior to diagnosis: case-control study using electronic health records from ambulatory care within a large US-based tertiary care centre.
Prado MG; Kessler LG; Au MA; Burkhardt HA; Zigman Suchsland M; Kowalski L; Stephens KA; Yetisgen M; Walter FM; Neal RD; Lybarger K; Thompson CA; Al Achkar M; Sarma EA; Turner G; Farjah F; Thompson MJ
BMJ Open; 2023 Apr; 13(4):e068832. PubMed ID: 37080616
[TBL] [Abstract][Full Text] [Related]
6. A new understanding of clinical patterns in post-TB lung disease.
Thomson H; Baines N; Huisamen T; Koegelenberg CFN; Irusen EM; Mapahla L; Allwood BW
Int J Tuberc Lung Dis; 2024 Mar; 28(3):115-121. PubMed ID: 38454184
[TBL] [Abstract][Full Text] [Related]
7. Patient-reported symptoms and diagnostic journey in Multiple Myeloma.
Vijjhalwar R; Song K; Shrestha R; Bowcock S; Sanchez-Santos MT; Ramasamy K; Javaid MK
Front Oncol; 2023; 13():1282569. PubMed ID: 38098501
[TBL] [Abstract][Full Text] [Related]
8. Results of screening in early and advanced thoracic malignancies in the EORTC pan-European SPECTAlung platform.
Morfouace M; Novello S; Stevovic A; Dooms C; Janžič U; Berghmans T; Dziadziuszko R; Gorlia T; Felip E; Paz-Ares L; Mazieres J; O'Brien M; Bironzo P; Vansteenkiste J; Lacroix L; Dingemans AC; Golfinopoulos V; Besse B
Sci Rep; 2022 May; 12(1):8342. PubMed ID: 35585228
[TBL] [Abstract][Full Text] [Related]
9. FDG Uptake on Positron Emission Tomography Correlates with Survival and Time to Recurrence in Patients with Stage I Non-Small-Cell Lung Cancer.
Kwon W; Howard BA; Herndon JE; Patz EF
J Thorac Oncol; 2015 Jun; 10(6):897-902. PubMed ID: 25811445
[TBL] [Abstract][Full Text] [Related]
10. Three-arm, randomized, phase 2 study of carboplatin and paclitaxel in combination with cetuximab, cixutumumab, or both for advanced non-small cell lung cancer (NSCLC) patients who will not receive bevacizumab-based therapy: An Eastern Cooperative Oncology Group (ECOG) study (E4508).
Hanna NH; Dahlberg SE; Kolesar JM; Aggarwal C; Hirsch FR; Ramalingam SS; Schiller JH
Cancer; 2015 Jul; 121(13):2253-61. PubMed ID: 25740387
[TBL] [Abstract][Full Text] [Related]
11. Age and Gender Variations in Cancer Diagnostic Intervals in 15 Cancers: Analysis of Data from the UK Clinical Practice Research Datalink.
Din NU; Ukoumunne OC; Rubin G; Hamilton W; Carter B; Stapley S; Neal RD
PLoS One; 2015; 10(5):e0127717. PubMed ID: 25978414
[TBL] [Abstract][Full Text] [Related]
12. 2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer.
Eberhardt WE; De Ruysscher D; Weder W; Le Péchoux C; De Leyn P; Hoffmann H; Westeel V; Stahel R; Felip E; Peters S;
Ann Oncol; 2015 Aug; 26(8):1573-88. PubMed ID: 25897013
[TBL] [Abstract][Full Text] [Related]
13. Implementation of lung cancer screening: promises and hurdles.
Prosch H
Transl Lung Cancer Res; 2014 Oct; 3(5):286-90. PubMed ID: 25806313
[TBL] [Abstract][Full Text] [Related]
14. Lung Cancer: Clinical Presentation and Diagnosis.
Latimer KM
FP Essent; 2018 Jan; 464():23-26. PubMed ID: 29313654
[TBL] [Abstract][Full Text] [Related]
15. Lung cancer: diagnosis, treatment principles, and screening.
Latimer KM; Mott TF
Am Fam Physician; 2015 Feb; 91(4):250-6. PubMed ID: 25955626
[TBL] [Abstract][Full Text] [Related]
16. Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial.
de Koning HJ; van der Aalst CM; de Jong PA; Scholten ET; Nackaerts K; Heuvelmans MA; Lammers JJ; Weenink C; Yousaf-Khan U; Horeweg N; van 't Westeinde S; Prokop M; Mali WP; Mohamed Hoesein FAA; van Ooijen PMA; Aerts JGJV; den Bakker MA; Thunnissen E; Verschakelen J; Vliegenthart R; Walter JE; Ten Haaf K; Groen HJM; Oudkerk M
N Engl J Med; 2020 Feb; 382(6):503-513. PubMed ID: 31995683
[TBL] [Abstract][Full Text] [Related]
17. Anticipated time to seek medical advice for possible lung cancer symptoms and barriers to timely presentation in Palestine: a national cross-sectional study.
Elshami M; Sawafta N; Mansour A; Alser M; Al-Slaibi I; Abukmail H; Shurrab H; Qassem S; Usrof FD; Alruzayqat M; Aqel W; Nairoukh R; Kittaneh R; Habes YMN; Ghanim O; Aabed WA; Omar O; Daraghma M; Aljbour J; Elian REM; Zuhour A; Habes H; Al-Dadah M; Albarqi SI; Bottcher B; Abu-El-Noor N
BMC Cancer; 2024 Feb; 24(1):183. PubMed ID: 38326766
[TBL] [Abstract][Full Text] [Related]
18. Clinical Trials for Oral, Inhaled and Intravenous Drug Delivery System for Lung Cancer and Emerging Nanomedicine-Based Approaches.
Aryal S; Park S; Park H; Park C; Kim WC; Thakur D; Won YJ; Key J
Int J Nanomedicine; 2023; 18():7865-7888. PubMed ID: 38146467
[TBL] [Abstract][Full Text] [Related]
19. The presenting symptom signatures of incident cancer: evidence from the English 2018 National Cancer Diagnosis Audit.
Zakkak N; Barclay ME; Swann R; McPhail S; Rubin G; Abel GA; Lyratzopoulos G
Br J Cancer; 2024 Feb; 130(2):297-307. PubMed ID: 38057397
[TBL] [Abstract][Full Text] [Related]
20. Identification of Potent Inhibitors Targeting EGFR and HER3 for Effective Treatment of Chemoresistance in Non-Small Cell Lung Cancer.
Dera AA; Zaib S; Areeba ; Hussain N; Rana N; Javed H; Khan I
Molecules; 2023 Jun; 28(12):. PubMed ID: 37375404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
